Quanterix (NASDAQ: QTRX) reported Q1 EPS of ($0.53), $0.10 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $30.3 million versus the consensus estimate of $28.22 million.

2025 Full Year Business Outlook

In assessing recent cuts to academic research funding, biopharma spending patterns, and tariffs, for 2025, on a standalone basis excluding the planned acquisition of Akoya, the Company expects to report revenues in a range of $120 million to $130 million, which represents a year-over-year revenue decline of 5% to 13%. This estimate excludes revenue from Lucent Diagnostics testing. The Company expects GAAP gross margin to be in the range of 55% to 59%, and adjusted gross margin (non-GAAP) in the range of 50% to 54%. Finally, the Company anticipates 2025 adjusted cash burn to be approximately $35.0 million to $45.0 million.

For earnings history and earnings-related data on Quanterix (QTRX) click here.